B

BioXcel Therapeutics
D

BTAI

1.76000
USD
-0.02
(-0.85%)
مغلق
حجم التداول
3,067
الربح لكل سهم
-9
العائد الربحي
-
P/E
-0
حجم السوق
9,623,747
أصول ذات صلة
A
ALLO
0.02000
(1.19%)
1.70500 USD
B
BLUE
-0.15000
(-3.69%)
3.91000 USD
C
CRSP
0.520
(1.38%)
38.220 USD
E
EDIT
0.01500
(0.93%)
1.63000 USD
GILD
GILD
0.420
(0.41%)
103.660 USD
N
NTLA
0.20000
(2.32%)
8.83000 USD
PFE
PFE
0.065
(0.27%)
24.185 USD
REGN
REGN
15.98
(2.71%)
606.12 USD
S
SGMO
-0.01210
(-1.63%)
0.72800 USD
VRTX
VRTX
2.22
(0.45%)
500.92 USD
المزيد
الأخبار المقالات

العنوان: BioXcel Therapeutics Inc

القطاع: Healthcare
الصناعة: Biotechnology
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.